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Abstract
Cystic Fibrosis (CF) lung disease, which is characterized by airway obstruction, chronic bacterial
infection, and an excessive inflammatory response, is responsible for most of the morbidity and
mortality. Early in life, CF patients become infected with a limited spectrum of bacteria, especially
P. aeruginosa. New data now indicate that decreased depth of periciliary fluid and abnormal
hydration of mucus, which impede mucociliary clearance, contribute to initial infection. Diminished
production of the antibacterial molecule nitric oxide, increased bacterial binding sites (e.g., asialo
GM-1) on CF airway epithelial cells, and adaptations made by the bacteria to the airway
microenvironment, including the production of virulence factors and the ability to organize into a
biofilm, contribute to susceptibility to initial bacterial infection. Once the patient is infected, an
overzealous inflammatory response in the CF lung likely contributes to the host's inability to
eradicate infection. In response to increased IL-8 and leukotriene B4 production, neutrophils
infiltrate the lung where they release mediators, such as elastase, that further inhibit host defenses,
cripple opsonophagocytosis, impair mucociliary clearance, and damage airway wall architecture.
The combination of these events favors the persistence of bacteria in the airway. Until a cure is
discovered, further investigations into therapies that relieve obstruction, control infection, and
attenuate inflammation offer the best hope of limiting damage to host tissues and prolonging
survival.
Introduction
Cystic fibrosis (CF) is an autosomal recessive disease
caused by lack of function of a cAMP-regulated chloride
channel, called CFTR (for the cystic fibrosis transmem-
brane conductance regulator), which normally resides at
the apical surface of many epithelial cell types. Epithelial
cells in the sweat glands, salivary glands, airways, nasal
epithelium, vas deferens in males, bile ducts, pancreas,
intestinal epithelium, as well as many other sites normally
express CFTR. The function of CFTR is important in many
of these organs, for its absence causes disease. However,
the most important site of disease, which accounts for
much of the morbidity and mortality in CF, is the lung.
Early in life, patients become infected with bacteria, and
eventually Pseudomonas aeruginosa becomes the predomi-
nant organism. Chronic infection leads to bronchiectasis,
respiratory failure, and death [1]. The mechanism by
which a defect in chloride transport leads to suppurative
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disease in the lung, but not elsewhere, is only now being
elucidated.
Vulnerability to infection in CF occurs only in the airways,
and not at other sites such as skin or urinary tract, so there
is no systemic immune defect in CF. However, excess
inflammation occurs at other sites: the prevalence of
inflammatory bowel disease and pancreatitis is markedly
increased [2,3]. Nevertheless, there is unquestionably
something special about the lung, which is intended to be
sterile, yet is continuously challenged by inhaled patho-
gens. Bacteria, when inhaled in small quantities, are ordi-
narily cleared without provoking significant
inflammation. The lungs of patients with CF do not deal
with this challenge appropriately. In this review, we ask
two questions: Why do the lungs of patients with CF
become infected? And why do they not clear these
infections?
Why do CF patients become infected?
Mechanical factors
In the lung, the CFTR channel is found in surface airway
epithelial cells and the cells of the submucosal glands [4].
Recent functional data indicate that there may be CFTR
expression in the alveolar epithelium [5], and some of the
migratory cells in the lung as well, including lymphocytes
[6]. However, the most obvious defects in the lungs of CF
patients appear to arise from defective salt transport across
the airway epithelium and failure to properly hydrate air-
way secretions. CFTR is a cAMP-regulated chloride chan-
nel, so in CF, chloride secretion through CFTR (and any
chloride channel whose activity depends on active CFTR,
such as the outwardly rectifying chloride channel) is
reduced, as is the amount of water which follows the salt.
Although the calcium regulated chloride channel is upreg-
ulated in CF, this channel, at least in the murine airway,
appears not to contribute to surface fluid depth. In the
basal state, the depth of airway surface fluid in CF mice is
reduced compared to normal mice [7]. Since calcium-reg-
ulated chloride channels induce secretion when stimu-
lated in both normal and CF murine airways, reduced
basal state fluid depth in CF patients indicates the lack of
participation of such channels in the maintenance of
basal state fluid balance. In addition, CFTR lives up to its
name as a "conductance regulator" and affects the func-
tion of many other channels in the epithelium [8]. Nota-
ble among them is the amiloride-sensitive epithelial
sodium channel (ENaC), which accounts for the bulk of
salt and water transport in the airways [9]. ENaC is
expressed in airway and alveolar epithelium, and is
responsible for the reabsorption of sodium (with water
following) from airway surface liquid. Such resorption is
necessary to maintain the relatively constant depth of air-
way surface fluid in spite of marked reduction of cross sec-
tional area of the airway surface from the alveoli to the
trachea. ENaC is downregulated by functional CFTR: in
the absence of CFTR function, ENaC activity increases
[10–13]. This increase in activity increases salt and water
reabsorption across the epithelium. The combination of
increased resorption and decreased secretion results in too
little fluid in the airways of patients with CF, although the
ionic composition of the fluid remains normal [14–18].
Although it is difficult to measure salt and water content
of airway surface directly in uninfected lungs of patients
with CF, it is possible to make such measurements in mice
engineered with defects in CFTR. The first such mouse to
be developed was the S489X mouse, a "knockout" mouse
in which a stop codon has been inserted at position 489.
Since this first mouse was engineered, several other
knockout mice and mice with the ∆F508 mutation and
other amino acid substitutions have been produced.
These mice, for the most part, lack function of the CFTR
chloride channel. However, their clinical manifestations
differ from those of humans. The CF mice reliably have
intestinal obstruction, which is usually the dominant and
fatal manifestation. On the other hand, these mice do not
spontaneously develop lung infection, though they are
more vulnerable to direct inoculation with various CF
pathogens. This feature allows pristine, uninfected lungs
with the CF ion transport defect to be studied. Direct
measurements of sodium, chloride, potassium, and cal-
cium concentrations, as well as osmolarity, in the airway
surface liquid in the trachea of living CF and non-CF mice,
and measurements in well-differentiated cultured airway
epithelial cells grown at the air-liquid interface support
this "isotonic, low-volume" hypothesis for the result of
the ion transport abnormalities in the airways of patients
with CF [7,14–18]. Measured ion composition and osmo-
larity of the airway surface liquid is comparable in CF and
non-CF mice. However, the depth of the airway surface
fluid is less in CF mice, and fluid volume is reduced atop
well-differentiated CF airway epithelial cell cultures com-
pared to non-CF. The "low volume" hypothesis predicts
that reduced airway surface liquid volume interferes with
proper ciliary function, reducing mucociliary clearance. In
CF mice, mucociliary clearance also is reduced. However,
reductions in mucociliary clearance have been difficult to
demonstrate unequivocally in CF patients. The measure-
ments themselves are quite variable, which may be part of
the difficulty, although the same techniques demonstrate
changes in mucociliary clearance with drug interventions,
as well as the markedly reduced mucociliary clearance that
occurs in patients with primary ciliary dyskinesia. Inter-
pretation of results in CF patients is complicated by the
secondary effects of disease, which are unevenly distrib-
uted throughout the lung. Nevertheless, since failure of
mucociliary clearance is an important link in the logical
chain connecting CFTR dysfunction with infection in theRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
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"low volume" model, it seems important to evaluate this
mechanism further in patients.
Besides abnormal periciliary fluid depth, the CF defect
probably leads to abnormal mucus hydration as well.
Mucus is packaged into granules before secretion and
unfolds during the secretory process. The water content of
CF mucus is reduced, even at sites that are not infected
(such as the uterine cervix) [19]. This reduced water con-
tent may contribute to abnormal properties that make
mucus difficult to clear in CF. However, in experimental
model systems, clearance is affected only in minor ways
over a wide range of viscosity and hydration of mucus
[20,21]. Therefore, it is likely that other factors combine
with the properties of the mucus itself to produce the
putative reduction in mucociliary clearance in CF.
During the later stages of disease, impaction of mucus and
failure of mucociliary clearance are unequivocally present.
In patients with bronchiectasis, stagnant pools of secre-
tions collect in the saccular dilations of the bronchi. His-
tological evaluation of CF airways from patients who have
died, or undergone lung transplantation or resection,
show that dense plaques of mucus become adherent to
the epithelial surface, at least during the later stages of dis-
ease in these patients. Bacteria in this mucous layer cannot
be cleared normally. It is not certain that such dense
mucus plaques plastered to the airway wall occur in the
earlier stages of disease. However, as the disease
progresses, stagnation of secretions and failure to clear
bacteria clearly contributes to the maintenance of pulmo-
nary infection.
Failure to kill bacteria properly
Prior to birth, the lungs are bathed in amniotic fluid, and
appear to be normal in CF. At the time of birth, however,
marked changes in fluid flux across the airway occur, the
air-liquid interface at the epithelial surface is established,
and the pattern of ion transport is altered. On histopatho-
logic examination of the lungs of uninfected neonates
with CF who died of meconium ileus, there was little his-
topathology and no inflammation. However, there is wid-
ening of the orifices of the submucosal glands, as if
already, in the prenatal period, plugging of the ducts has
occurred [22]. However, airway tissue retrieved from CF
fetuses and implanted into the backs of immunosup-
pressed mice shows submucosal collection of neutrophils,
which do not reach the lumen unless some stimulus is
applied [23]. These xenografts also appear to produce an
excess of interleukin (IL)-8, and so may be primed to
respond vigorously to inflammatory stimuli [24]. After
birth, the infant airway is challenged repeatedly with
small doses of bacteria. Nonspecific airway defenses such
as defensins, lysozyme, and nitric oxide (NO) ordinarily
dispatch these small inocula. However, in the airways of
patients with CF, the non-specific defenses may be com-
promised. Although there has been considerable atten-
tion paid to the possibility of defective function of
defensins in the airways of patients with CF, it now
appears that these molecules are intact and function nor-
mally. However, the major isoform of nitric oxide syn-
thase (NOS) in airway epithelial cells, NOS-2, is reduced
in CF airway epithelium [25]. Reduction in local NO pro-
duction probably compromises the host's ability to han-
dle small bacterial inocula.
The lack of NOS-2 expression in CF airway epithelial cells
appears to be related directly to CFTR function. In CF
mice, NOS-2 expression in epithelia is markedly reduced
[25]. In CF mice in which the basic defect is partially cor-
rected by transgenic expression of human CFTR driven by
the FABP promoter in the gut only, NOS-2 expression is
restored only in the epithelium of the gut, not in the air-
way. In mice that have received human CFTR by gene
transfer; the cells that show the immunohistochemical
signal of hCFTR also have NOS-2 activity restored. Similar
results are obtained in CF models in cell culture. Cells
with a CF phenotype have markedly reduced NOS-2
expression at the mRNA and protein level compared to
their matched non-CF controls. These results are also con-
firmed by immunohistochemical staining for NOS-2 in
human postmortem tracheal samples. At first glance,
reduction in NOS-2 expression in the airways of patients
with CF is puzzling because NOS-2 is transcribed in
response to nuclear factor-kappaB (NF-κB) activation,
which is known to be increased in the CF epithelium.
However, NOS-2 transcription also requires phosphor-
ylated signal transducer and activator of transcription
(Stat)-1. Further investigation demonstrated that Stat-1 is
present in abundance in the CF epithelial cells and is nor-
mally phosphorylated. However, the protein inhibitor of
activated Stat 1 is also markedly upregulated [26]. This
protein binds to phosphorylated Stat-1 and prevents its
transcriptional activity. This mechanism predicts that
other Stat-1 regulated proteins might also be downregu-
lated in CF. This prediction is confirmed for interferon
regulatory factor-1 and regulated on activation normal T
cell expressed and secreted. Thus, dysregulation of Stat-1
activity may well have broad functional consequences in
CF for the defense of the airway.
One hypothesis for the specific defense of the airway
against inhaled P. aeruginosa is that CFTR itself constitutes
a specific receptor for this organism [27]. If CFTR is lack-
ing at the airway epithelial surface, then this receptor is
absent. Once bound to CFTR, P. aeruginosa are internal-
ized, the epithelial cell undergoes apoptosis, and is
sloughed, thereby clearing the internalized organisms.
However, this hypothesis does not explain how patients
with activation or channel mutants of CFTR, that reach theRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
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cell surface (e.g., G551D), are just as vulnerable to P. aer-
uginosa infection as are patients that lack CFTR at the cell
surface.
If the nonspecific defenses of the airway are compro-
mised, this, in combination with reduced clearance of
bacteria, may supply a stimulus sufficient to recruit an
inflammatory response in the CF airway, whereas a com-
parable bacterial challenge to a normal infant would sim-
ply result in killing by nonspecific host defense
mechanisms and efficient clearance. Once the bacteria ini-
tiate an inflammatory response, many other systems are
called into play, some of which are deleterious to the
airway.
Abnormal retention of specific bacteria in the airway
The post-translational modification of cell surface and
secreted molecules may be altered to facilitate binding of
P. aeruginosa and other infecting agents. Several mecha-
nisms for retention of bacteria in the airways of patients
with CF have been proposed. Asialo-GM1, a ligand for P.
aeruginosa, S. aureus, and H. influenzae, is increased on CF
airway epithelial cells [28], sufficient to explain a two-fold
increase in bacterial binding [29], a modest change, but
one which could become important over time. Some
investigators have questioned the importance of adher-
ence, since histopathologic examination reveals relatively
few bacteria in apposition to the epithelial surface, sug-
gesting that the dense mucus layer may prevent access
[30,31]. However, these studies were performed on sam-
ples taken at autopsy or transplantation, and thus repre-
sent end-stage lung disease. At this point, bacteria have
adapted to their environment by a downregulation of the
genes for pilin and flagelin, two important epithelial
adhesins. Even at this late stage in the disease process,
however, other bacteria, notably Burkholderia cepacia, can
penetrate the mucus layer and even the epithelial barrier
[32], suggesting that the dense mucus is not an absolute
barrier to epithelial access. Earlier in the disease process,
however, when pilin and flagelin are expressed by P. aeru-
ginosa, the classical infectious disease paradigm of adher-
ence followed by infection may still be valid. In addition,
even if surface binding of bacteria is not quantitatively
important in the establishment of infection, it may be
important for the initiation of an exuberant inflammatory
response [33]. The binding of pilin to asialo-GM1 acti-
vates the pro-inflammatory transcription factor NF-κB
and induces production of the neutrophil chemoattract-
ant IL-8 [34,35]. Flagelin, like pilin, extends from the bac-
terial cell surface and promotes P. aeruginosa retention in
the airways of patients with CF by binding to mucin oli-
gosaccharides via flagellar cap protein FliD [36,37] and to
epithelial cell oligosaccharides where it stimulates the
production of pro-inflammatory cytokines [38]. Specific
attachment of bacteria, combined with the putative com-
promise of mucociliary clearance as a direct result of the
salt transport defect, promotes retention of bacteria in the
mucus of the airways of patients with CF and allows them
to multiply there. The relationship between mutant CFTR
and these pathophysiologic processes is shown in Figure
1.
Adaptation of bacteria to live in the CF airway
It is impossible to consider the host's response to infec-
tion without considering the character of the infecting
organisms. In CF, chronic endobronchial bacterial infec-
tions display a limited spectrum of organisms including
H. influenzae, S. aureus, P. aeruginosa, B. cepacia, Stenotro-
phomonas maltophilia, and Alcaligenes xylosoxidans [39,40].
While H. influenzae and S. aureus may predominate early
in life, over 30% of patients three years of age and 80% of
young adults are chronically infected with P. aeruginosa
[39–41], a ubiquitous and highly adaptable, aerobic,
Gram-negative bacillus that is motile by means of a single
polar flagellum. It is non-pathogenic in normal hosts, but
becomes a pathogen in individuals with weakened
defenses [42]. P. aeruginosa, like a few other CF pathogens,
has the ability to develop resistance to multiple antibiot-
ics. The mechanism of resistance is in large part due to the
presence of efflux pumps, which, in addition to antibiot-
ics, export detergents, dyes, and homoserine lactones [43].
Also, the CF airway confers special selective advantages to
P. aeruginosa. Some strains of P. aeruginosa have the ability
to mutate rapidly in the lungs of patients with CF. These
hypermutable strains demonstrate an increased ability to
resist antibiotics [44]. In explanted lung tissue obtained
from end-stage CF patients, some investigators demon-
strated that P. aeruginosa resides primarily within the
intraluminal mucus [45], thus suggesting that the muco-
ciliary escalator is an important host defense mechanism
for those bacteria trapped in mucus (Fig. 2). In the airways
of patients with CF, P. aeruginosa initially continues its
usual non-mucoid phenotype, but ultimately produces
mucoid exopolysaccharide (MEP) or alginate, which gives
its colonies their typical appearance. A steep oxygen con-
centration gradient exists between the airway lumen and
the interior of the mucus [45]. P. aeruginosa responds to
the hypoxic environment of mucus by producing even
more MEP [45,46], which contributes to the persistence of
P. aeruginosa in the CF airway by interfering with host
defenses and delivery of antibiotics to the bacterial cell.
Although MEP is highly antigenic, antibodies directed
against it are not effective opsonins, but they can partici-
pate in formation of immune complexes that intensify
local tissue damage [47–49]. P. aeruginosa also produces
an alginate lyase enzyme that cleaves MEP and may allow
spread of the organism to contiguous sites [50]. Although
the conversion to mucoidy typically is associated with
decreased virulence [51], the decline in lung function that
occurs in CF is actually accelerated after P. aeruginosaRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
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assumes the mucoid phenotype [52]. This implies that the
progressive deterioration in lung function experienced by
a CF patient is due more to the long-term deleterious
effects of host inflammatory responses rather than direct
damage from the bacteria itself. Residence in the CF lung
also seems to alter the properties of P. aeruginosa lipopol-
ysaccharide (LPS): LPS isolated from a large percentage of
CF patients has little or no O-side chain, conferring a
rough appearance to colonies when grown on agar plates.
Changes at this site in the molecule may have clinical
implications because complement fixation occurs on the
O-side chain. Furthermore, P. aeruginosa may synthesize
specific structures in the lipid-A moiety of its endotoxin,
which provoke increased host inflammatory responses
and resistance to antimicrobial peptides [53]. In addition
to the advantages conferred upon it by the appropriate
environmental conditions, P. aeruginosa itself possesses
special characteristics that allow it to persist in the lungs
of patients with CF, including the production of virulence
factors and the ability to organize into a biofilm.
Impact of mutant cystic fibrosis transmembrane conductance regulator (CFTR) on cellular physiology Figure 1
Impact of mutant cystic fibrosis transmembrane conductance regulator (CFTR) on cellular physiology. Mutant CFTR promotes 
initial bacterial infection by upregulating epithelial cell adhesion molecules for bacteria such as asialo-GM1 and by decreasing 
production of innate host defense molecules such as nitric oxide (NO). Defects in CFTR also lead to increased sodium absorp-
tion through the epithelial sodium channel (ENaC) and decreased chloride secretion. Water follows its concentration gradient 
and results in decreased depth of airway surface liquid. Bacterial persistence is promoted by alterations in airway wall architec-
ture, impaired host defense mechanisms, an excessive inflammatory response, and adaptations made by the bacteria to the 
microenvironment of the cystic fibrosis airway.Respiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
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Numerous P. aeruginosa virulence factors contribute to its
pathogenicity in CF by altering the host's defenses. Pseu-
domonas elastase and alkaline protease are proteolytic
enzymes that may damage host tissues, disrupt tight junc-
tions, and impair opsonophagocytosis [54]. Pseu-
domonas elastase degrades immunoglobulins,
coagulation factors, complement components, cytokines,
and alpha proteinase inhibitor [55] and stimulates mucin
release from goblet cells [56], likely enhancing the already
increased production of mucin that occurs in the CF air-
way. Pseudomonas elastase is more potent than neu-
trophil elastase, on a per mg basis, with respect to elastin
degradation, and thus may contribute to CF lung pathol-
ogy, even though the predominant elastase in CF sputum
is from neutrophils [57]. Exotoxin A promotes tissue
necrosis by inhibiting protein synthesis in eukaryotic cells
by a similar mechanism to that described for diphtheria
toxin. Exotoxin A catalyzes the transfer of the ADP-ribosyl
moiety of nicotinamide adenine dinucleotide onto elon-
gation factor 2, which then is inactive in protein synthesis.
Exotoxin A also attracts neutrophils into the lungs of mice
[58]. Exoenzyme S is an ADP-ribosyltransferase that
Schematic Representation of the mucociliary escalator in the non-cystic fibrosis and cystic fibrosis (CF) airways Figure 2
Schematic Representation of the mucociliary escalator in the non-cystic fibrosis and cystic fibrosis (CF) airways. In the non-CF 
airway (Fig. 2A), where the depth of the periciliary fluid is normal, islands of mucus float on top and are propelled upward 
toward the mouth by the coordinated beating of cilia. In the CF airway (Fig 2B), the mucus is poorly hydrated and hypoxic. 
Because of the decreased depth of the periciliary fluid, the abnormal mucus is plastered down upon the cilia, thus inhibiting 
normal ciliary beating. Eventually the bacteria present in the airway become trapped in the mucus and adapt to the local envi-
ronment. In the case of P. aeruginosa, this includes production of mucoid exopolysaccharide (MEP) and organization into a 
biofilm.Respiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
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disrupts eukaryotic cell signal transduction, stimulates
actin reorganization, inhibits tissue regeneration, serves as
a potent T lymphocyte mitogen, maintains the site of
infection by promoting P. aeruginosa adhesion, and is
cytotoxic, especially to epithelial cells, [59–64]. Phos-
pholipase C hydrolyzes lecithin, decreases the neu-
trophil's respiratory burst, and stimulates IL-8 release by
monocytes in vitro. It also induces local production of
tumor necrosis factor-alpha (TNF-α), IL-1β, interferon-
gamma, macrophage inflammatory protein-1α, and mac-
rophage inflammatory protein-2 in addition to stimulat-
ing neutrophil infiltration, thereby likely contributing to
the vigorous inflammatory response seen in the CF airway
[58]. Pigments such as pyocyanin bind iron, inhibit the
growth of other bacteria, and inhibit ciliary beat fre-
quency [65,66]. Since P. aeruginosa virulence factors
increase with acute pulmonary exacerbations and
decrease after the administration of systemic antibiotics
[67,68], virulence factors may contribute, at least in part,
to acute deteriorations in lung function.
Recently, the ability of P. aeruginosa to organize into a bio-
film has garnered much attention. Donlan and Costerton
define a biofilm as "a microbially derived sessile commu-
nity characterized by cells that are irreversibly attached to
a substratum or interface or to each other, are embedded
in a matrix of extracellular polymeric substances that they
have produced, and exhibit an altered phenotype with
respect to growth rate and gene transcription" [69]. Bio-
film formation protects bacteria from changes in environ-
mental conditions, antibiotics, and host defenses, and
thus may consolidate the ability of the bacterium to per-
sist in the airways of patients with CF. Bacteria within a
biofilm communicate with one other via a mechanism
known as quorum sensing, which also downregulates vir-
ulence factors, allowing the bacteria to live in symbiosis
with the host [70]. The altered phenotype of bacteria in a
biofilm may have clinical importance. Growth character-
istics differ significantly for bacteria in a biofilm than for
those in the free-living, planktonic state. Antibiotic sensi-
tivity testing performed on bacteria in the planktonic
state, as occurs in the clinical microbiology laboratory,
may not accurately reflect the true sensitivities of bacteria
in a biofilm [71]. This difference may account for the clin-
ical efficacy of macrolide antibiotics that has been
described in CF [72,73]. Quorum sensing signals provide
a promising potential therapeutic target in CF.
No article on bacterial infections in CF would be complete
without at least mentioning B. cepacia. What was once
thought to be a single organism, "B cepacia" actually
includes several related organisms now known as B. cepa-
cia complex [74,75]. Although infrequent pathogens in
CF, organisms of the B. cepacia complex often have major
clinical impact. The clinical course after acquisition of B.
cepacia complex organisms spans the spectrum of no dis-
cernable clinical change to severe and rapidly progressive
respiratory failure, often associated with bacteremia and
death ("cepacia syndrome") [75]. Organisms of the B.
cepacia complex, especially the organisms implicated in
cepacia syndrome, have been proposed to provoke a more
robust host inflammatory response than P. aeruginosa
with respect to production of TNF-α by monocyte cell
lines in vitro, neutrophil recruitment, and priming of the
neutrophil respiratory burst [76,77]. However, this
increased inflammatory response has not been docu-
mented in CF patients [78].
Chronic endobronchial bacterial infection with one or
more typical organisms is the hallmark of CF lung disease.
The host inflammatory response in CF to the bacterial
infection dictates the clinical manifestations of the lung
disease. In general, CF patients experience a progressive
decline in pulmonary function that is punctuated by inter-
mittent exacerbations, which are characterized by
increased cough, sputum production, anorexia, and
malaise. Antimicrobial therapy for CF bacterial infections,
especially for P. aeruginosa, frequently requires the admin-
istration of a combination of two or more antibiotics due
to the bacteria's ability to become resistant to a single
agent. Moreover, CF patients typically require greater than
normal antibiotic doses to penetrate the large endobron-
chial mucus sink and to counter the altered pharmacoki-
netics that occur in CF patients due to increased volume
of distribution from malnutrition and, for some drugs,
increased renal clearance [42]. Most CF patients return to
pre-exacerbation pulmonary function values after com-
pleting a course of parenteral antibiotics, but this is not
always the case. It is possible that the cumulative effects of
multiple pulmonary exacerbations contribute to the
decline in lung function and that those patients with more
frequent and/or severe exacerbations have shorter life
spans.
Why do patients with CF fail to clear bacterial 
infection?
Excess inflammation provides an environment favorable to 
bacterial growth
CF infants develop bacterial infection early, and respond
to it with a vigorous inflammatory response. Epithelial
cells respond to bacteria and their products by increasing
production of cytokines such as IL-6, IL-8, granulocyte
macrophage colony stimulating factor (GM-CSF), expres-
sion of intercellular adhesion molecule-1, and production
of mucins. IL-8, a potent chemokine, attracts neutrophils
to the inflammatory site, where their transepithelial pas-
sage is facilitated by intercellular adhesion molecule-1
and their survival prolonged by GM-CSF. When lung mac-
rophages encounter bacteria, they respond not only by
producing their own IL-8, but also by producing TNF-αRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
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and IL-1β, which in turn can drive epithelial cell produc-
tion of pro-inflammatory molecules by a signaling
pathway different from that accessed by the bacterial
products. Quickly, the airway recruits large numbers of
neutrophils, which early in the course of the infection, are
often able to contain the bacteria. Initial infections are fre-
quently cleared, and colonization that is only intermittent
is common in the first few years of life.
The inflammatory process appears to go awry in the lungs
of patients with CF, even in infancy. Clinical studies indi-
cate that, for a given lung bacterial burden, the neutrophil
and IL-8 responses of CF infants, measured in bronchoal-
veolar lavage fluid, are excessive compared to those of
normal infants. This is true whether all organisms recov-
ered from the lung are considered, or whether analysis is
restricted only to infants whose cultures reveal only H.
influenzae [79,80]. Inflammation is in excess in CF even if
the neutrophil and IL-8 responses are adjusted for the
amount of endotoxin in the bronchoalveolar lavage. Ini-
tially, this response seems to contain the bacteria. Indeed,
in other, cross-sectional studies of inflammatory
responses in CF bronchoalveolar lavage fluid, many CF
infants have no detectable bacteria, but even some of
these infants have a modest inflammatory response,
which exceeds that observed in other, uninfected, non-CF
infants undergoing bronchoalveolar lavage [81]. How-
ever, other studies show that at least some CF infants, par-
ticularly those who have never had lung infection, have
no detectable inflammatory response [82]. The picture
emerges of a lung which, although initially pristine and
uninflamed, mounts an excessive inflammatory response
to bacterial stimulation, which continues to reverberate
even after the infection is controlled. Eventually, all the
factors, which serve to retain bacteria in the CF lung, over-
whelm the defenses of the lung, even the phagocytic
defenses, and the bacterial signals for inflammation per-
sist. At this point, the excessive inflammatory response
becomes deleterious and even promotes continuing
infection.
One striking feature of CF airways disease is the progres-
sive accumulation of neutrophils over a period of years.
This "acute inflammation" never converts to a more
"chronic" pattern. Since neutrophils do not survive long
after exiting the circulation, there must be a persistent
stimulus to attract these neutrophils. There is certainly an
excess of chemoattractants such as IL-8 and leukotriene B4
recovered in bronchoalveolar lavage fluid [83,84]. Bacte-
ria provide additional chemoattractants. The neutrophils
may survive longer in the airways of patients with CF
because of the production of excess GM-CSF and the rela-
tive lack of IL-10 [83,85,86], which, when present, pro-
motes neutrophil apoptosis. When present in excess,
neutrophils and their products actually impair the host's
ability to clear bacterial infection. Neutrophil elastase, in
particular, interacts with airway epithelial cells to promote
the transcription of IL-8 and macromolecular secretion,
further fueling airway inflammation and obstruction [87–
91]. Elastase cleaves IgG at the hinge region [92,93]. Since
macrophages use antibodies to ingest P. aeruginosa,
opsonophagocytosis is reduced in the presence of excess
elastase. On the other hand, neutrophils employ comple-
ment for opsonophagocytosis of P. aeruginosa. This system
consists of two receptors, CR-1 and CR-3 and two comple-
ment opsonins, C3b (ligand for CR-1) and C3bi (ligand
for CR-3). Elastase cleaves the CR1 receptor and the C3bi
ligand, so that neither of the opsonin-receptor pairs is left
intact [94,95]. Thus, all the usual mechanisms of inges-
tion of P. aeruginosa are crippled in the presence of free
elastase activity (Fig. 3). In one study of CF patients, all
patients above the age of one year, and many of those less
than one year of age, had excess neutrophil elastase activ-
ity in their bronchoalveolar lavage fluid [96]. Most
patients over 1 year of age have concentrations in excess of
1 µM. Since the opsonins and receptors are cleaved at con-
centrations of free elastase of 10-8 M, 1 µM is more than
sufficient to turn the vicious cycle of inflammation and
infection, and to destroy the fabric of the lung.
Structural damage to the lung allows for mechanical 
retention of secretions and retention of bacteria
We have argued here that inflammation in the CF lung
occurs in excess compared to the response mounted by
non-CF individuals, and that it is ultimately ineffective
against the bacteria. The result of all this is that CF infants
develop bacterial infections very early in life. In the begin-
ning, colonization may be intermittent, but eventually, it
becomes chronic. The special binding properties of P. aer-
uginosa, combined with its ubiquitous presence in our
environment and therefore regular exposure, and its par-
ticular ability to adjust quickly and perfectly to conditions
in the CF lung likely account for its predilection for the CF
lung. Eventually most patients with CF acquire this organ-
ism, develop a vigorous and persistent neutrophilic
inflammatory response, and settle into a vicious cycle of
airway obstruction, infection, and excess inflammation
that results in lung destruction, further damage to the
clearance processes, and additional vulnerability to infec-
tion or phenotypic transformation of the P. aeruginosa
into a biofilm, which is impossible to eradicate despite
the most vigorous antibiotic therapy.
The persistent bacterial stimulation of an overzealous
inflammatory response results in excess neutrophils and
neutrophil products in the airways. Many of the proteases
secreted by the neutrophil are capable of digesting the
structural proteins of the CF lung, including collagen and
elastin. Small breaks in the epithelial barrier expose these
structural proteins, and the normal antiprotease defensesRespiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
Page 9 of 12
(page number not for citation purposes)
are overwhelmed by the massive quantities of enzymes
released by the enormous neutrophil infiltration. Reactive
oxygen species are also potent agents of tissue damage.
The antioxidant defenses of the lung are markedly
reduced in CF, although the reasons for this are not
entirely clear. It has been speculated that CFTR transports
glutathione as well as chloride ion, and in the absence of
functional CFTR, less glutathione reaches the airway to
defend against oxidant damage. In any event, reduced oxi-
dant defenses can be demonstrated even in the uninfected
airways of CF mice [97]. Another class of proteases is also
elevated in the bronchoalveolar lavage fluid of patients
with CF. Matrix metalloproteinases, implicated in remod-
eling of inflamed areas of the lung, are found in excess in
the lungs of patients with CF. These proteinases can be
produced by epithelial cells, and their transcription is acti-
vated by NF-κB. All of these damaging proteases and oxi-
dants combine to destroy the supporting structures of the
airway and ultimately lead to bronchiectasis. Once the
fabric of the airway wall is compromised, outpouching of
the airway wall (saccular bronchiectasis) occurs. In these
damaged areas, pooling of secretions and failure of clear-
Adverse effects of elastase on host defense mechanisms and inflammation Figure 3
Adverse effects of elastase on host defense mechanisms and inflammation. In the cystic fibrosis airway, the concentration of 
elastase exceeds the concentration of inhibitors of elastase by several hundred to several thousand fold. While the vast major-
ity of elastase is produced by the neutrophil, a small but significant amount is derived from bacteria. In addition to causing 
structural damage directly, elastase stimulates the production of pro-inflammatory mediators such as IL-8, which further 
induces neutrophil influx. Elastase also impairs mucociliary clearance by direct effects on ciliary function and by stimulating 
increased mucus production. Elastase inhibits opsonophagocytosis by cleaving the Fc portion of immunoglobulin G and comple-
ment receptors on both the neutrophil (CR1) and P. aeruginosa (C3bi), resulting in an opsonin-receptor mismatch.Respiratory Research 2003, 4 http://respiratory-research.com/content/4/1/8
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ance is inevitable. It is rare that infection can be cleared
once such structural damage has occurred. In the later
stages of the disease, all of the complications of bron-
chiectasis of any cause emerge in patients with CF –
engorgement of the bronchial blood vessels with risk for
massive hemoptysis, persistent secretions and cough, and
persistent bacterial infection that is impossible to clear.
However, all of the features noted above that allow bacte-
ria to be retained in the CF lung in the first place are still
present, and all of the abnormalities in signaling that
make for increased inflammatory responses are also in
play. Therefore, the progression of bronchiectasis in the
lungs of patients with CF tends to be more rapid than it is
in patients with bronchiectasis of other causes, such as
post-infectious bronchiectasis or bronchiectasis associ-
ated with primary ciliary dyskinesia. Many patients with
bronchiectasis of non-CF etiology survive well into adult-
hood or even old age, whereas such survival is rare in
patients with CF.
Summary and conclusions
The lungs of patients with CF are vulnerable to bacterial
infection, and once the infection becomes established, it
is not eradicated despite prolonged and vigorous antibi-
otic and airway clearance therapy. This aspect of the dis-
ease has long provided an inviting therapeutic target,
though it is essentially a rear guard action which delays
but does not prevent the progression of the lung disease.
Successful strategies to prevent the initial colonization,
assist in the clearance of initial infections, prevent the
adaptation of P. aeruginosa to the CF lung environment, or
even to limit the excess inflammatory response (although
not the response required to kill the bacteria), would have
great therapeutic benefit to patients with CF. Indeed, a
number of strategies have been proposed to interfere at
each of these steps: aerosolized dextrans to prevent pseu-
domonas adherence, intravenous IgG to assist in clear-
ance, and many proposed anti-inflammatory treatments
to limit the excessive inflammation already have reached
clinical trial. Once infection has been established, lung
damage might be slowed by inhibiting the excess of oxi-
dants in the CF airway or by inhibiting the proteolytic
damage to the structural proteins of the airways with anti-
proteases (or, at a more fundamental level, limiting the
access of the neutrophils to the airway). Drugs aimed at
these steps are also in development. Strategies directed at
the basic defect, if applied sufficiently early in the course
of the disease, might abort the entire process and provide
the best therapeutic result of all. Once structural damage
has occurred, however, bronchiectasis may take on a life
of its own, and even complete correction of the underly-
ing genetic defect may not completely halt disease pro-
gression. For these patients, further development of the
means to control the inflammatory response and its con-
sequences likely will be necessary.
Abbreviations
CF cystic fibrosis
CFTR cystic fibrosis transmembrane conductance
regulator
ENaC epithelial sodium channel
GM-CSF granulocyte macrophage colony stimulating
factor
IL interleukin
LPS lipopolysaccharide
MEP mucoid exopolysaccharide
NF-κB nuclear factor-kappaB
NO nitric oxide
NOS nitric oxide synthase
Stat signal transducer and activator of transcription
TNF-α tumor necrosis factor-alpha
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